Discussion Panel: The Future of Causality Assessment: Is it Wise: Will it Help? What Effect Could it Have on the Analysis of Clinical Trial Data or in Pharmacoepidemiology?

Abstract

Panelists: Dr Hyman Zimmerman VA Medical Center, Washington, DC; Dr Bruce Wintroub, Department of Dermatology, VA Medical Center, San Francisco, California; Dr Winifred M. Castle, Medical Advisor, Product Safety Group, Medical Department, Imperial Chemicals Industries PLC, Pharmaceuticals Division, Macclesfield, Cheshire, United Kingdom; Dr Bruce Hill, Professor, Department of Statistics, University of Michigan, Ann Arbor, Michigan; Dr David Lane, Department of Theoretical Statistics, University of Minnesota, Minneapolis; Dr Tom A. Hutchinson, Nephrology Division, Royal Victoria Hospital, Montreal, Quebec, Canada; Dr Michael Kramer, Department of Epidemiology & Biostatistics, Montreal, Quebec; Professor Rolf Hoigné, Head, Medical Division, Ziegerspital, Switzerland; Dr David J. Spiegelhalter, Medical Research Council, MRC Centre, United Kingdom; and Dr. Jan Venulet, Ciba-Geigy Medical Department, Basel, Switzerland